Citizens JMP Reiterates Market Outperform Rating on Altimmune (ALT)

Citizens JMP analyst Jonathan Wolleben reiterated a Market Outperform rating and $25.00 price target on Altimmune (NASDAQ: ALT).

The analyst commented, “Altimmune’s (ALT, MO, $25 PT) pemvidutide will be featured in an oral presentation on Saturday (6/22) highlighting cardio-inflammatory lipidomic analyses. While the abstract remains under embargo until June 13, ALT has previously presented data showing pemvidutide reduced lipid species associated with systemic inflammation and CV disease in obese, non-diabetics. ALT will present three posters on pemvidutide, focusing on its effectiveness in reducing visceral adipose tissue mass, its impact on cardiovascular risk, and its role in reverse cholesterol transport. The next key catalyst for ALT shares is the Phase 2b IMPACT data in MASH coming sometime this month.”

For an analyst ratings summary and ratings history on Altimmune click here. For more ratings news on Altimmune click here.

Shares of Altimmune closed at $5.49 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Honeywell's Quantinuum Raises $1.68 Billion In US IPO
• Bitmine Immersion Technologies plans $300 million preferred stock offering